Stockreport

CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

CARGO Therapeutics, Inc.  (CRGX) 
PDF - 57 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel); on track for interim analysis in 1H25 - - CRG-023 [Read more]